GLUT1 is an important target in cancer therapy, and its inhibition may represent an effective approach to overcoming cancer cell resistance; the small molecule WZB117 inhibits GLUT1 expression and sensitizes breast cancer cells to ionizing radiation [49]. Here, SLC2A1 is linked to cancer.